Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Even as the US and countries across Europe and Asia report a rise in measles cases, Microsoft co-founder and billionaire philanthropist Bill Gates said that eradicating measles is currently impossible.

The reason? Vaccine hesitancy, particularly in wealthy countries such as the US, Gates said, according to Reuters.

“At one point, the Gates Foundation wanted to eradicate measles, but the vaccine hesitancy in rich countries has meant that’s not on our list of goals,” Gates said. “I think that’s kind of tragic.”

How Big Is The Measles Outbreak In The US?

Also read: Pennsylvania Reports 3rd Measles-Related Death; 40-Year-Old Dies As Outbreak Spreads Across 37 Counties

According to the CDC, 3,294 confirmed measles cases have been reported in the US so far in 2026.

There have also been 38 new outbreaks reported this year, with 95% of confirmed cases associated with outbreaks — 1,748 cases from outbreaks that started in 2026 and 1,375 from outbreaks that started in 2025.

For comparison, 2,289 confirmed measles cases were reported in the US during the entire year of 2025.

So far this year, three deaths — two babies and one adult — have been reported from Pennsylvania, one of the worst-hit states. The state has also reported four measles cases among people who were fully vaccinated this year.

Measles can be prevented by vaccination. However, the anti-vaccine stance promoted by the Trump-led US government and HHS Secretary RFK Jr. are resulting in spiraling cases. More recently, Trump also announced a split of the MMR vaccine, which experts warn can have consequences.

Measles was considered eliminated in the US since 2000, but the Pan American Health Organization is expected to decide in November whether the US has lost its elimination status.

How Effective Is The MMR Vaccine?

The measles, mumps and rubella (MMR) vaccine is recommended for children. The first dose is given at 12-15 months, followed by a second dose between 4-6 years.

Two doses of the measles vaccine are 97% effective at preventing measles. However, breakthrough infections can still occur.

Among people who have received one dose of the vaccine, about seven out of 100 may develop measles after exposure, according to the CDC.

The measles vaccine is safe for most people. However, people with certain medical conditions, including a weakened immune system, may need to take additional precautions.

An infected person can spread the virus to around nine out of 10 unvaccinated people who are exposed. Measles can cause serious complications, including pneumonia, brain inflammation and death.

Read More: Donald Trump Signs Order To Split MMR Vaccine: Is It Safe For Children?

Global Measles Rise

Measles is one of the world's most contagious diseases and can cause high fever, cough and a characteristic rash.

The WHO estimates that 95,000 people died from measles globally in 2024, despite vaccination having prevented an estimated 59 million deaths since 2000.

The WHO says vaccination coverage needs to remain above 95% to prevent outbreaks.

Recent years have also seen a surge in measles cases in countries where the disease had become rare, including the US and parts of Europe, as vaccination coverage has fallen.

Bangladesh Battles Major Measles Outbreak

Bangladesh was once close to eliminating measles but is now battling one of the world's largest measles outbreaks.

According to Bangladesh health ministry data, 1,022 deaths have been associated with the outbreak, including 100 laboratory-confirmed measles fatalities.

More than 166,000 suspected cases have been reported, including nearly 20,000 laboratory-confirmed infections. More than 146,000 suspected patients have also been hospitalized.

For the first time, the US Congress is set to hold a dedicated hearing on menopause, putting a long-overlooked women’s health issue under the national spotlight. Convened by Sen. Kirsten Gillibrand (D-N.Y.), the hearing will be held by the Senate Committee on Aging.

Titled “Half the Country, Zero Hearings: Meeting the Moment to End the Menopause Care Gap in America,” the hearing will focus on the gaps in menopause research and care in the US.

Gillibrand is the senior Democrat on the committee and can lead one hearing each year on a topic of her choice. She chose menopause.

“It's time to talk about menopause. Half of our country will go through it, yet it is one of the most under-researched, undertreated, and underdiagnosed fields of medicine,” the 59-year-old Democrat leader shared in a post on X.

“This week, I'm holding the first-ever congressional hearing on menopause to demand high-quality research and care for women across America,” she added.

Why Is Menopause Getting Congressional Attention?

Gillibrand has described menopause as an issue that has long been ignored, particularly amid debates over the Trump administration’s scientific research cuts and health care affordability.

Also read:‘I Was Vocal About Cancer But Silent About Menopause Out Of Shame’, Says Actress Lisa Ray

She said the hearing also aims to address the impact of menopause symptoms on women’s lives and sexual health.

“We spend billions of dollars on Viagra to make sure men can have sex — what have you done to make sure women can have sex?” she said, the New York Times reported.

Gillibrand also plans to call for bipartisan legislation to boost federal research on menopause.

Menopause Care Gap In The US

“I’ve used my one hearing on the most under-researched, underreported, underanalyzed issue for women’s health, ever,” Gillibrand said. “From 50 to 58, I had either night sweats or hot flashes. I had to really look for a doctor who could take me through the hows and the whys and the impacts.”

Read More: Is Hormone Replacement Therapy (HRT) A Boon To Women's Health During Menopause?

Gillibrand said the government has long failed to devote federal resources to menopause and contended that the Trump administration has made the situation worse.

She cited the Food and Drug Administration’s recent decision to remove so-called black box warnings from all hormone replacement products containing estrogen.

“I’m wondering why they want women to have less information,” she said.

What Is Menopause?

Menopause marks the end of a woman’s reproductive years and occurs when menstruation permanently stops.

Clinically, it is diagnosed after 12 consecutive months without a menstrual period.

Most women experience menopause between 45 and 55, although perimenopause can begin several years earlier.

During perimenopause, the ovaries gradually produce less estrogen and progesterone, the hormones that regulate the menstrual cycle. This hormonal decline can cause symptoms that vary widely among women.

While common symptoms including hot flashes and night sweats, sleep disturbances, mood changes and irritability and vaginal dryness, for some women the drop in estrogen levels can also be associated with health concerns including osteoporosis, heart disease and, in some cases, metabolic disorders.

Regular health checkups, balanced nutrition and physical activity during midlife are important. Hormone Replacement Therapy may also help manage menopause symptoms for some women, depending on their individual health profile and medical history.

Popular GLP-1 drugs Ozempic, Wegovy, Mounjaro and Zepbound have transformed the treatment of type 2 diabetes and obesity. However, a new study suggests they may be linked to a rare but serious brain disorder caused by vitamin B1 (thiamine) deficiency.

Researchers from Israel’s Sheba Medical Center identified 15 cases of Wernicke’s encephalopathy (WE) among people taking GLP-1 medications containing semaglutide or tirzepatide.

The findings suggest that nutritional deficiencies, particularly of vitamin B1, also known as thiamine, may contribute to the development of Wernicke’s encephalopathy.

What Did the Study Find?

Published in Clinical Nutrition, the study examined 195,979 cases and identified 15 reports of WE in 2023 and 2024.

Most patients experienced gastrointestinal problems, including severe vomiting, loss of appetite, malnutrition or rapid weight loss. These factors can reduce food intake and increase the risk of vitamin B1 deficiency.

Only two patients had the classic symptoms of WE: altered mental status, difficulty walking and abnormal eye movements.

Researchers described the findings as a potential safety signal and called for greater clinical awareness, particularly among patients experiencing severe gastrointestinal symptoms.

“WE is a potentially rare but severe adverse event of GLP-1 RA treatment, mainly with semaglutide or tirzepatide,” the researchers said. “As early detection may prevent neurological sequelae, increased clinical awareness is warranted, especially in individuals experiencing severe gastrointestinal symptoms.”

Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor

Can GLP-1 Drugs Cause Vitamin Deficiency?

GLP-1 drugs suppress appetite and can reduce food intake, potentially limiting consumption of vitamin B1-rich foods such as pork, fish and whole grains.

Vitamin B1 is essential for proper nerve function. Without enough of it, patients can develop confusion, problems with balance and coordination, and abnormal eye movements.

In its early stages, thiamine deficiency can cause vague, nonspecific symptoms such as headaches, fatigue, irritability and abdominal discomfort.

Researchers said the findings should help doctors educate patients about the potential risk and monitor for warning signs.

What Is Wernicke’s Encephalopathy?

Wernicke’s encephalopathy is a rare neurological disorder caused by severe vitamin B1 deficiency. Symptoms can include confusion, problems with coordination and abnormal eye movements.

The classic symptom triad is often absent, making the condition difficult to recognize. If untreated, WE can cause permanent neurological damage, progress to Korsakoff syndrome or result in death. Korsakoff syndrome is a permanent condition marked by memory loss, confusion, and changes in personality.

READ: GLP-1 Weight Loss Drugs Ozempic, Wegovy, Mounjaro Tied To Over 60 Reported Deaths In Australia

Should You Take Supplements?

Experts do not recommend routinely taking supplements with GLP-1 drugs unless a deficiency is confirmed or nutritional needs cannot be met through diet.

A balanced diet containing fruits and vegetables, whole grains, nuts and seeds, dairy or fortified alternatives, and lean or plant-based proteins can help maintain adequate nutrient intake.

Experts also caution that products marketed specifically as “GLP-1 support” supplements may have limited evidence behind their claims.